Clinical trials: B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma
Erythropoietin for Management of Anemia Caused by Chemotherapy
This is a phase Ⅱ study of erythropoietin for management of anemia caused by chemotherapy in patients with Diffuse Large B-cell Lymphoma.
- Trial name
- NCT02890602
- Testing
- Darbepoetin alfa, R-CHOP
- Volunteers
- 53 people
- Sponsor
- Kosin University Gospel Hospital
B-Cell Lymphoma
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
- Trial name
- NCT02395601
- Testing
- CPI-1205
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Constellation Pharmaceuticals
Non-Hodgkin Lymphoma Refractory/ Relapsed
Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).
- Trial name
- NCT06334991
- Testing
- CD19 t-haNK
- Where
- 3 sites in South Africa
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Recurrent or Refractory B Cell Malignancy
Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
Cluster of differentiation antigen 19(CD19) specifically presents in B lymphocyte cell lines steadily,while not in most normal tissue,including pluripotent hematopoietic stem cells.Cluster of differentiation antigen 20(CD20)…
- Trial name
- NCT03207178
- Testing
- Mixed CD19/CD20 CAR-T Transfer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Longyao Biotechnology Inc., Ltd.
Diffuse Large B Cell Lymphoma
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Trial Subjects (patients), will receive single infusions of pembrolizumab in combination with CXD101 every 3 weeks for two years or until disease progression or unacceptable toxicity develops.
- Trial name
- PLACARD (NCT03873025)
- Testing
- Pembrolizumab and CXD101
- Sponsor
- University College, London
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the…
- Trial name
- NCT04304040
- Testing
- Orelabrutinib, Recombinant humanized monoclonal antibody MIL62 injection
- Where
- 10 sites in China
- Volunteers
- 43 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
B-cell Lymphoma
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
This Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety and tolerability of SL1617 Injection in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07775508
- Testing
- SL1617 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese PLA General Hospital
Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma
Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years
This study is a multicentric, phase II, open-label, non-randomized trial evaluating the efficacy of O-miniCHOP in patients aged over 80 years with non previously treated CD20+ diffuse large B-cell lymphoma (age-adjusted IPI=0…
- Trial name
- NCT01195714
- Testing
- Ofatumumab
- Where
- 84 sites in Belgium, France
- Volunteers
- 120 people
- Sponsor
- The Lymphoma Academic Research Organisation
Leukemia, Lymphoma
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus.
- Conditions
- Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
- Trial name
- NCT00006340
- Testing
- arginine butyrate, ganciclovir
- Where
- 6 sites in United States, France and 2 more
- Sponsor
- Boston Medical Center
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL).
- Trial name
- EPCORE™ NHL-2 (NCT04663347)
- Testing
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Genmab
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma.
- Trial name
- NCT06445517
- Testing
- ISM8207
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
- Trial name
- NCT06393335
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Primary Mediastinal Lymphoma
Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
This compares the effects of nivolumab at a fixed dose of 40 mg with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).
- Trial name
- NCT06188676
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- National Research Center for Hematology, Russia
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
In patients with relapsed or refractory diffuse DLBCL who have not achieved complete remission in the mid-term, the treatment with Glofit+GemOx regimen is used.
- Trial name
- NCT07480850
- Testing
- Glofitamab, Gemcitabin, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma.
- Trial name
- NCT02420210
- Testing
- Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.